Peter Lang

14PUBLICATIONS
144CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Sensor technology (incl. chemical aspects)HaematologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|May 29, 2026
A pilot study combining primary busulfan-based haploidentical stem cell transplantation with GD2 antibody to treat high-risk neuroblastoma.

|Jan 11, 2025
Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort Study.

Tim Flaadt, Jonas Rehm, Thorsten Simon

|Dec 03, 2024
Elevated Soluble ACE2 Activity in Children and Adults After SARS-CoV-2 Exposure Irrespective of Laboratory-Confirmed Infection.

Maximilian Stich, Vladimir Gonçalves Magalhães, Friederike Bürger

|Feb 07, 2024
Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppression.

Barbara Meissner, Peter Lang, Peter Bader

|Oct 14, 2023
Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse.

Tim Flaadt, Martin Ebinger, Malin Schreiber

|Jul 04, 2023
Defining the landscape of circular RNAs in neuroblastoma unveils a global suppressive function of MYCN.

Steffen Fuchs, Clara Danßmann, Filippos Klironomos

Pageof 3

Frequent Collaborators

5 joint publications

Roland Meisel

4 joint publications

Thorsten Simon

4 joint publications

Tim Flaadt

3 joint publications

Brigitte Strahm